^
    1m
    Myriad Genetics announces foundational patent granted for Molecular Residual Disease (MRD) with early priority date (Myriad Genetics Press Release)
    "Myriad Genetics...announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market."
    Patent
    |
    Precise™ MRD
    2ms
    Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 (GlobeNewswire)
    "Myriad Genetics, Inc...today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients diagnosed with a wide array of solid tumor and hematological cancers...The SCRUM-MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino of the NCCHE, will explore how multi-omic profiling can be used to develop more personalized treatment and therapeutic strategies in three study cohorts."
    Licensing / partnership • Minimal residual disease
    |
    Precise™ MRD
    4ms
    Precise™ MRD: Commercial launch in 2H 2025 (Myriad Genetics)
    J.P. Morgan 42nd Annual Healthcare Conference Presentation
    Launch
    |
    Precise™ MRD
    over1year
    Precise MRD: Launch for RUO in mid-23 (Myriad Genetics)
    Investor Presentation
    Launch
    |
    Precise™ MRD